Ansa Biotechnologies Inc., a leading partner in DNA synthesis, has announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer. Hamilton will report to CEO Jason T. Gammack and will oversee the company’s financial management, corporate strategy, and strategic partnerships as Ansa accelerates its growth in biotechnology, synthetic biology, and pharmaceutical markets.
Health Technology Insights: Hippocratic AI Accelerates Team Growth and Key Executive Hires
Jason T. Gammack, CEO of Ansa Biotechnologies, stated that Hamilton brings extensive experience in guiding companies through transformative periods. He added that Geoff’s record of scaling teams, products, and businesses is exactly what Ansa needs as it expands its operations and commercial presence.
Ansa’s first year of commercial activity has been fueled by growing demand for its long, complex, and sequence-perfect synthetic DNA, which is guaranteed under its Ansa On-Time Guarantee. Traditional chemical DNA synthesis methods limit researchers to short and simple sequences, but modern applications in cell and gene therapy, genome engineering, bioproduction, and advanced biologics require longer, more complex DNA constructs. Ansa’s enzymatic platform addresses this challenge by providing accurate, verified DNA up to 50 kilobases and setting new standards for reliability.
Health Technology Insights: Auna and Sojitz Partner to Expand Healthcare in Latin America
Gammack emphasized that Hamilton’s arrival will accelerate Ansa’s ability to redefine what researchers can expect from their DNA synthesis partners. He said Geoff’s experience in navigating industry-defining transitions will be key as the company pushes boundaries in synthetic biology.
Geoff Hamilton brings more than 25 years of leadership experience in life sciences and medical devices. He co-founded and served as CEO of Stemson Therapeutics, a cell therapy company developing curative treatments for hair loss. He has also held senior leadership roles at Illumina, Life Technologies, and Stryker, where he led financial planning, commercial strategy, partnerships, product development, and global launches that shaped high-growth market segments. He holds a bachelor of science in business administration from the University of North Carolina at Chapel Hill and actively supports career transitions for U.S. Special Operations veterans through The Honor Foundation.
Hamilton said he is excited to join Ansa at a pivotal time for DNA synthesis, which he believes is poised for a transformation similar to the genome sequencing boom twenty years ago. He highlighted the company’s technological breakthroughs, commercial momentum, and highly reliable manufacturing platform as key factors that will allow researchers to move beyond limitations in DNA design and fully embrace genome-scale engineering. Hamilton emphasized that transparent pricing, guaranteed service, and rigorous quality standards set a new benchmark for the industry.
All Ansa DNA products are manufactured in the United States and are designed to integrate seamlessly into existing laboratory workflows. The company follows strict biosecurity practices and complies fully with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening.
Health Technology Insights: Quanterix Strengthens Leadership with Board Appointments
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
